Share Name Share Symbol Market Type Share ISIN Share Description
Integumen Plc LSE:SKIN London Ordinary Share GB00BYWJ6269 ORD 0.01P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 1.00 8,957,920 14:07:39
Bid Price Offer Price High Price Low Price Open Price
0.98 1.02 1.06 0.925 1.025
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Personal Goods 0.27 -2.12 1.00 1.0 11
Last Trade Time Trade Type Trade Size Trade Price Currency
15:11:53 O 100,000 1.00 GBX

Integumen (SKIN) Latest News (3)

More Integumen News
Integumen Takeover Rumours

Integumen (SKIN) Discussions and Chat

Integumen Forums and Chat

Date Time Title Posts
30/3/202012:25Integumen - Skin in the Game9,779
12/7/201907:51Integumen82
26/2/201914:05True Judaism a means to a co-existance with Non-Jews9
06/4/201711:44Skin in the Game2

Add a New Thread

Integumen (SKIN) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
14:11:551.00100,0001,000.00O
13:30:261.0020,000200.00O
13:16:001.0028,690288.05O
13:07:401.026486.61O
13:07:401.022502.55O
View all Integumen trades in real-time

Integumen (SKIN) Top Chat Posts

DateSubject
30/3/2020
09:20
Integumen Daily Update: Integumen Plc is listed in the Personal Goods sector of the London Stock Exchange with ticker SKIN. The last closing price for Integumen was 1p.
Integumen Plc has a 4 week average price of 0.76p and a 12 week average price of 0.76p.
The 1 year high share price is 2.53p while the 1 year low share price is currently 0.76p.
There are currently 1,072,416,903 shares in issue and the average daily traded volume is 3,340,084 shares. The market capitalisation of Integumen Plc is £10,724,169.03.
30/3/2020
10:01
tickboo: I've got 2.875m in MWG (a lot more here) as as well as investing in a PLCs technology/USPs, market size, potential it's about leaders and who's looking strategically to create a sustainable and robust business model. Although SKIN's share price is shocking raising money when he did yes was lucky timing-wise but imagine trying to do so now, large cos would be even more nervous signing lengthy deals with a weak balance sheet.£2m of orders in Q1 so easy double last year and 3 Qs to go. Remember -If you missed 18 mths of #Integumen RNS's2018: Sold "#skin as a consumable" deal size £3k2019: Sold "skin microbiome R&D services" deal size £30k2020: Skin services and bacteria reagents deal size £1m (up 33,233%)Labs in 2018 924 sq.ft. Labs in 2020 6000 sq.ft (up 550%)
05/3/2020
11:08
tickboo: I'm looking in here a lot less frequently but given the share price/chart it's tricky to argue with the bears. I listened to the presentation and being a shareholder here it gave me confidence. I realise it's not a regulated RNS but nothing out of turn was stated and although the share price hasn't responded it's obvious the market wants to see some material contract wins rather than revenue-sharing deals that will be material (as per a recent RNS). The nature of the framework agreements are such that there will be multiple purchase orders for a single client throughout the year which aren't material but cumulatively should be well over 6 figures and up to £500,000. There is a slide that has 6 of the top 20 cosmetic cos who are in framework agreements and have purchase orders between £99,000 and £27,000 with L'Occitane at £33,000 so the average purchase order is £55,500. Say they'll need more tests every 3 months and with these 6 clients alone that is nearly £2m per annum. GB said given these agreements if they continue doing what they're doing they expect £3m and that excludes revenue-sharing deals, new pitches etc. Remember with the EU rules coming into play in May I for one expect these massive cosmetic cos to increase the number of ingredients/products being tested. Yes the share price is painful and I doubt until we have some more concrete RNSs new shareholders will be jumping on board as the chart looks terrible but I have faith and think the RNSs we've had this year have been great and I expect the market to catch up. That said, given the share price it's easy for the bears to crow. That's what makes a market! I'm looking forward not backwards and although I didn't seee the last raise coming SKIN needed the cash to for due diligence depts if large cos who wanna make sure SKIN will be around for the duration of any agreement. Sufficient cash for growth.
23/12/2019
21:06
yump: OK, so clearly my attempt to smooth things out has been refused and you are just carrying on. So I will, until you make the first move. You have no idea what my track record is. You say you're not interested in the past. With investments, that is probably the most dangerous attitude you could have, particularly with something like SKIN and its connections and history. Ignoring that is just plain foolish in the extreme. If you want to repeat the same mistakes over and over, that's the way to do it. So try and find some proper arguments or go back to school. I'm sure people can make up their own minds whether any of your posts on this or any other threads have any merit, as they can with mine. The main difference as far as I can see is that you remain pointlessly positive whatever the situation is, whereas if I think something is dodgy or stinks, I'll say so. If I could be bothered, I'd post a long list of my 'this is never going to make it' posts from other stocks from various years. You would see that most of them now are trashed, a fraction of what they were, or delisted stocks. As I said before, someone warned me about Venn but I ignored it and bought in. Venn was useless, Integumen was part of it and loss-making so they floated it off (nice work if you can get it) in an attempt to make Venn profitable - which failed. SKIN share price plummeted, then GB started on it. Meanwhile Venn turned into ORPH and got rid of its (highly promising according to you ??!!) SKIN shares. If you actually think that amongst all the possible investments you could make, that this one is one of the best, then I hope you have all the luck in the world. You'll need it.
10/12/2019
11:23
tickboo: Worth a re-post - I have read the comments and wondered whether anyone commenting negatively actually read the RNS or just the headline. Yes, it is unusual for a CEO to be on ADVFN, but that is just me. I will continue to do so, without compromising EU 2016 MAR conditions.Integumen are growing so fast, that it is necessary to either slow down, turn business away, or keep accelerating. To do that requires hiring more staff to deal with the increased demand, larger laboratories and business development team to cover US, EU and Asia.Directors followed their investment with £48k.The largest institutional shareholder increased their holding by twice that.The first 6 months of 2018 this company was generating $54,000 (in total sales) with £274k for full-year 2018We guided £1m for 2019 or 300% growth over and above 2018We guided £4m for 2020 or 300% growth over and above 2019We are adding on laboratory capacity to be able to cope with revenues up to £10m. That is 10 times 2019 revenues, which is 187.5% growth over and above 2020In addition. the Labskin teams are working with multiple large partners in the EU and US on projects that exceed £10m.At 78% gross margin and data generating as much as twice the Labskin side of the business, net margins are quite high, as can be seen from Q3 numbers with operating costs up, but losses down. We are heading into profitability in 2020.This funding was filled very fast, started and finished in 7 working days.The amount raised was the maximum (to the last share) that was agreed at the AGM on the 31st of July, this year.There are no investors warrants, as we did not have to because we are close to profitability. That risk is being eliminated.4% discount to Friday closing.8.5% dilution for triple-digit growth percentages.Large companies required the Company to have a cash buffer, which was highlighted during their due diligence. Why? Because, before agreeing to sign off on long term commitments to work with us, they want Integumen to prove the ability to fulfil our long term commitments to them. If they are relying on us for their future growth we have to verify we are adequately funded.Someone pointed out here in this thread this morning, if we told everyone we were going to raise funds, the price would have dropped to the floor. If we told anyone individually, that would be insider trading.As for the use of the term "forward selling". It is a myth. How can you undertake a T+10 sell last week, if the shares are not going to be on AIM until the 16th of December?Someone pointed out rightly, I believe, that no single negative poster on a bulletin board can drive a share price lower. Bad management, market sentiment, lack of communication to shareholders and ultimately sellers drive a share price lower.If you don't believe your own research or existing shareholders and management are not prepared to put their own money on the line, then you should not be invested.If some shareholders equate our fast growth to a likelihood of a risk of overtrading, where we could not fund growth, had to slow down, turn orders away, then they might assume we would need to raise funds, or growth would stall. But we did not acquire with massive dilution. It was enough for internal growth and to meet the demands of our large clients.Finally, if you are invested for the long term, you have considered compound interest growth of a company. From the above numbers, we are delivering triple-digit growth. This is no longer just from a very low value.Management is aligned with shareholders for that growth, and have continued to buy in since August 2018. We would not have taken shares in salary, nor invested more money today if we thought otherwise.Do your research and read more than just a headline.
09/12/2019
10:28
gjbrandon: I have read the comments and wondered whether anyone commenting negatively actually read the RNS or just the headline. Yes, it is unusual for a CEO to be on ADVFN, but that is just me. I will continue to do so, without compromising EU 2016 MAR conditions. Integumen are growing so fast, that it is necessary to either slow down, turn business away, or keep accelerating. To do that requires hiring more staff to deal with the increased demand, larger laboratories and business development team to cover US, EU and Asia. Directors followed their investment with £48k. The largest institutional shareholder increased their holding by twice that. The first 6 months of 2018 this company was generating $54,000 (in total sales) with £274k for full-year 2018 We guided £1m for 2019 or 300% growth over and above 2018 We guided £4m for 2020 or 300% growth over and above 2019 We are adding on laboratory capacity to be able to cope with revenues up to £10m. That is 10 times 2019 revenues, which is 187.5% growth over and above 2020 In addition. the Labskin teams are working with multiple large partners in the EU and US on projects that exceed £10m. At 78% gross margin and data generating as much as twice the Labskin side of the business, net margins are quite high, as can be seen from Q3 numbers with operating costs up, but losses down. We are heading into profitability in 2020. This funding was filled very fast, started and finished in 7 working days. The amount raised was the maximum (to the last share) that was agreed at the AGM on the 31st of July, this year. There are no investors warrants, as we did not have to because we are close to profitability. That risk is being eliminated. 4% discount to Friday closing. 8.5% dilution for triple-digit growth percentages. Large companies required the Company to have a cash buffer, which was highlighted during their due diligence. Why? Because, before agreeing to sign off on long term commitments to work with us, they want Integumen to prove the ability to fulfil our long term commitments to them. If they are relying on us for their future growth we have to verify we are adequately funded. Someone pointed out here in this thread this morning, if we told everyone we were going to raise funds, the price would have dropped to the floor. If we told anyone individually, that would be insider trading. As for the use of the term "forward selling". It is a myth. How can you undertake a T+10 sell last week, if the shares are not going to be on AIM until the 16th of December? Someone pointed out rightly, I believe, that no single negative poster on a bulletin board can drive a share price lower. Bad management, market sentiment, lack of communication to shareholders and ultimately sellers drive a share price lower. If you don't believe your own research or existing shareholders and management are not prepared to put their own money on the line, then you should not be invested. If some shareholders equate our fast growth to a likelihood of a risk of overtrading, where we could not fund growth, had to slow down, turn orders away, then they might assume we would need to raise funds, or growth would stall. But we did not acquire with massive dilution. It was enough for internal growth and to meet the demands of our large clients. Finally, if you are invested for the long term, you have considered compound interest growth of a company. From the above numbers, we are delivering triple-digit growth. This is no longer just from a very low value. Management is aligned with shareholders for that growth, and have continued to buy in since August 2018. We would not have taken shares in salary, nor invested more money today if we thought otherwise. Do your research and read more than just a headline.
13/11/2019
07:28
dafad: When we read todays rns and parity's client list and then apply it to the rns dated 29th of October then the opportunity is massive   Integumen Plc (LSE)Skinovation Pharmaceutical, Inc. (GM)(USOTC) Integumen Share News (SKIN)   Follow Alert Integumen PLC Launch of ind. Rinodrive AI open-source eco-system29/10/2019 7:00amUK Regulatory (RNS & others) Integumen (LSE:SKIN) Historical Stock Chart 1 Month : From Oct 2019 to Nov 2019 TIDMSKIN RNS Number : 3928R Integumen PLC 29 October 2019 AIM share code: SKIN 29 October 2019 Integumen PLC ("Integumen" or "Company") Integumen launches independent Rinodrive AI open-source eco-system Labskin AI demonstrates value of the Rinodrive data driven platform Integumen is pleased to announce the launch of Rinodrive (www.rinodrive.com) as an independent Artificial Intelligent (AI) platform for collaboration and joint venture partners as an open-source cloud-based eco-system. The stand-alone platform is currently being rolled out with existing healthcare clients, a growing list of higher educational establishments, being tested in government departments, in a reputable UK bank and an international financial advisory firm. Since 2016, Rinocloud, a wholly-owned subsidiary of Integumen, has developed Rinodrive as a data aggregation, refining and AI analysis open-source eco-system, designed to provide third-party service providers with the ability to offer their clients valuable insights that support clinical, operational and financial decisions in healthcare services, third-level education, government departments and the financial sector. Gerard Brandon CEO of Integumen commented: "Following the transformational change with the Integumen business model achieved in just a few months by adding AI to Labskin, we are now delighted to be able to offer the same benefits across multiple industries. Rinodrive will act as an independent AI platform which will allow the management of Integumen to remain focused on their core Labskin AI business while deriving revenues from clients across healthcare services, third-level education, government departments and the financial sector. "In the three years prior to the Rinocloud acquisition in May 2019, Rinodrive had been developed to deal with the explosive growth of data across multiple industries. We have seen it successfully work with genetic data at Labskin and also at various scientific data at research institutes such as the University College Cork, Cambridge University and the Centre for Advanced Photonics & Process Analysis at the Cork Institute of Technology. Rinodrive AI is now ready to help our clients and partners advance their work beyond Labskin and add a further revenue sharing source of income as we head into 2020." Explosive data growth It is estimated that the doubling time of medical knowledge in 1950 was 50 years and in 2010, the amount of healthcare data collected was said to be doubling every three and a half years. It is projected that by 2020 this will be every 73 days[i]. The International Data Corporation predicts a healthcare data compound annual growth rate of 36 % up to 2025 - driven by analytics, imaging and real-time data for decision support - exceeding manufacturing (30 %), finance (26 %) and media (25 %)[ii]. In order to ensure staff retention while at the same time improve quality of care, it is imperative that healthcare providers increase efficiency to reduce costs, waste, duplication and the length of the care to maintain patient satisfaction. Data is the key driver. Connecting existing systems with open platforms, and specialists with patients, while employing AI to analyse the data and generate actionable insights is key to the increase demands on any modern-day healthcare eco-system. Unexploited data Rinodrive is a robust platform with state-of-the-art open-source cloud infrastructure. Many Labskin clients already share their clinical trial results through the LabskinAI portal through secure, military grade encrypted access. The business opportunity for Rinodrive will be achieved through partnership, joint venture and revenue sharing collaboration. Consultant companies managing data aggregation and migration to the cloud can create value for the client from the use of Rinodrive AI tools on their client data. Likewise, recruitment companies supplying IT personnel in a highly competitive market for low-margin single fee income can transform their business model by targeting high margin clients contracting personnel to compete on equal terms with the likes of Accenture, McKinsey and other consultancy firms.
02/8/2019
08:48
homeboy: just to remind people - sorry lemmings this is the business model here imvhaebmo - "how its likely to pan out here - they'll put out some rns's to show progress, then they'll raise money again - dilution it'll be for some identified bolt on business probably owned by someone they know who'll do well out of being bought out. 20m skin now becomes 40m skin, but share price still near 2p thanks to the dilution, then they'll find another bolt on business and dilute again one day, skin is worth 100m, but strangely the share price is still at 2p, thanks to buying in market cap at the expense of dilutive fund raising, at a future point, skin has a 100 to 1 consolidation 2p now becomes 2 quid they then say, since we took over skin has been a major success, we built a 5m quid business into a 100m quid business, and the share price has grown to 2 quid, lol but no one makes any money except those whose businesses who were bought out. lol"
31/7/2019
08:09
soultrading: Another good update. Share price will have to move up soon or later. Wed, 31st Jul 2019 07:00 RNS Number : 2771H Integumen PLC 31 July 2019 AIM share code: SKIN 31 July 2019 Integumen PLC ("Integumen" or "Company") AGM - Trading Update Integumen issues the following update on current trading and outlook for the year, to coincide with the Company's Annual General Meeting taking place later today. Outlook The current level of pipeline activity continues to be significantly higher than the Company has experienced in the past. This has resulted in a requirement to increase the laboratory size by 100% in two announced upgrades in the last 12 months. Demand continues to increase for the company's products and services. The Board is satisfied that it is meeting its objective of increasing the average revenue per client as it evolves into a multiple revenue stream product and services company for skin related diseases, treatments and therapies. Post Year-End 2018 commercial activity: · After increased demand for services: o Labskin York, UK laboratory increased by 40% in H1; o Investment of £400,000 for hi-tech laboratory equipment; o Labskin York, UK laboratory space will increase by a further 50% in Q3 2019; o Offices opened in Cork, Ireland for IT, AI infrastructure support and global sales; · Four Blue-Chip (US and EU) client agreements signed for test services on household name soap and cosmetic brands to comply with EU Directive 745/2013 Rule 21 and EU 655/2013 · Labskin human volunteer bacteria cloning service launched that allows Integumen to enter the clinical trial and medical device sector. · First external development facility, at the digital hub enterprise zone within the University of Bradford and the Centre of Skin Science; · Following the positive results of Labskin Cannabinoid (CBD) testing protocols two CBD test contracts have been signed since the beginning of the year with eight contracts currently under negotiation; · STOER For Men skin products e-commerce division, continues to be used as a control for client testing within Labskin laboratories and remains at break-even; · Staff appointments, including Paul Ryan as Head of Enterprise sales will increase major client contracts and Colin O'Sullivan as AI Architect to ramp up the IT infrastructure to accommodate digital growth across the US, EU and Asia. · Wound pHase CBD development project agreement in place for new range of medical device wound care products for chronic diabetic wounds collaboration project with Cellulac, supported by EU Interreg grants and Irish Government state supported research facility tcbb Resource. Post Year-End 2018 corporate activity: · Transformational £3m all-share Acquisition of Rinocloud Limited enabling scale-up of the business as it moves from a physical laboratory to an automated, real-time, real-world digital data platform; · Successful fundraising of £2.75m (gross); of which, o £232k was Vendor sale to allow 100% of Rinocloud to be acquired; · Additional strategic reduction of the indebtedness of the business: · Disposal of Visible Youth Group - saving £245k of future contractual liabilities; · Debt conversions - Venn £421k carried over since April 2017 IPO; · Cellulac debt conversion - £400k for hi-tech laboratory equipment; · Litigation issues settled - saving £250k of future liabilities. o Labskin York, UK laboratory increased by 40% in H1; o Investment of £400,000 for hi-tech laboratory equipment; Legacy Share Trading matters: July 2019: Venn Life Sciences (Open Orphan) 30m held in soft lock-in: Open Orphan plc (formerly Venn Life Sciences Holdings plc ("Venn-OO")), was assisted in the disposal of Venn-OO's entire holding of 30,071,428 ordinary shares, representing 3.07%, of the Company. There being high liquidity and pent up demand for large blocks of shares in the Company, the Company broker arranged for an orderly disposal of the Venn-OO shares to be placed with existing long-term shareholders, thereby eliminating any overhang on the open market. May 2019: Venn Life Sciences 42m with no lock-in: On 5 April 2019, the 2-year lock-in that Venn Life Sciences plc entered into at the Integumen IPO in April 2017, expired. An RNS issued by Venn, on the 1 May 2019, confirmed that they had disposed of 42,244,682 ordinary shares. May 2019: Enhance Skin Products Inc. 38m with no lock-in: On May 22, Enhance Skin Products Inc ("Enhance") announced the settlement of its dispute with Integumen plc., and its plan to complete its plan of reorganisation, liquidation and dissolution. At that date Enhance held 29,488,144 wit a further 8,439,072 issued in respect of the settlement agreement. Following the further distribution of shares, which were not recognised as sale or transaction, the amount of shares now held by Enhance Skin Product Inc., is now 4,905,130 and Enhance is no longer a significant shareholder as ownership has fallen below 3%. The company is now satisfied that there is no longer a large overhang of shares in this matter. Ross Andrews - Non-Executive Chairman of Integumen plc, comments: "The Company has been completely transformed over the last 12 months. The objective of disposing of non-performing subsidiaries and incorporating fully integrated teams of skilled personnel, across multiple subsidiaries, with a single focus of increasing revenue per-existing client and closing bigger deals with new clients has been met. The growth of the Company has been so well supported and received by the market that all corporate activity has been achieved, funding in place to accommodate the continued growth, and legacy share disposals from former directors and associated companies have been absorbed by the market, leaving no overhang, as we head into an exciting second half of 2019. The Board is grateful for this support and looks forward to providing you with continued updates as we progress." Interim H1 2019 results are expected to be released in early September 2019
26/7/2019
09:05
homeboy: as posted before, this is what i think the business model will be - "how its likely to pan out here - they'll put out some rns's to show progress, then they'll raise money again - dilution it'll be for some identified bolt on business probably owned by someone they know who'll do well out of being bought out. 20m skin now becomes 25m skin, but share price still near 2p thanks to the dilution, then they'll find another bolt on business and dilute again one day, skin is worth 100m, but strangely the share price is still at 2p, thanks to buying in market cap at the expense of dilutive fund raising, at a future point, skin has a 100 to 1 consolidation 2p now becomes 2 quid they then say, since we took over skin has been a major success, we built a 5m quid business into a 100m quid business, and the share price has grown to 2 quid, lol but no one makes any money except those whose businesses who were bought out. lol"
20/7/2019
10:56
homeboy: how its likely to pan out here - they'll put out some rns's to show progress, then they'll raise money again - dilution it'll be for some identified bolt on business probably owned by someone they know who'll do well out of being bought out. 20m skin now becomes 25m skin, but share price still near 2p thank to the dilution, then they'll find another bolt on business and dilute again one day, skin is worth 100m, but strangely the share price is still at 2p, thanks to buying in market cap at the expense of dilutive fund raising, at a future point, skin has a 100 to 1 consolidation 2p now becomes 2 quid they then say, since we took over skin has been a major success, we built a 5m quid business into a 100m quid business, and the share price has grown to 2 quid, lol but no one makes any money except those whose businesses who were bought out. lol
Integumen share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
SKIN
Integumen
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200330 14:52:47